Personalized cancer vaccines

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

184 papers

Active filtersClassification:Core

Showing 1-12 of total 184 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026CrossrefDirectly related0 citations

Evaluation of Computational Neoantigen Prioritization Strategies for Personalized Cancer Vaccines

Vladimir Zyrin; Evgeniy Mozheiko; Ivan Valiev; Alexey Lazarev; Tigran Gevorkyan; Matvey Murashko; Konstantin Okonechnikov

Sep 28, 2026Vaccines

2026arXivDirectly related

Optimizing RNA yield using deep neural networks coupled to massively parallel screening

Dinghai Zheng; Justin Hong; Jun Wang; Adrien Villain; Mickaël Costallat; Fernando Ulloa Montoya; Vikram Agarwal

Aug 24, 2026

2026CrossrefDirectly related0 citations

Artificial intelligence in peptide cancer vaccine design: from neoantigen discovery to immunogenicity prediction

Petar Brlek; Jan Kolić; Luka Bulić; Vedrana Škaro; Dragan Primorac

Jul 29, 2026Frontiers in Genetics

2026CrossrefDirectly related0 citations

Neoantigen-Encoded Oncolytic Viruses as Personalized Cancer Vaccines

Almohanad A. Alkayyal

Feb 26, 2026Pharmaceuticals

2026PubMedSupporting evidence

Mechanisms of Resistance to Targeted Therapy in Epidermal Growth Factor Receptor (EGFR)- and Anaplastic Lymphoma Kinase (ALK)-Mutated Non-small Cell Lung Cancer: Molecular Basis, Emerging Biomarkers, and Therapeutic Strategies.

Dhillon S; Rathod H; Dhillon S

Jan 1, 2026Cureus

2026PubMedDirectly related

Self-Assembling Peptide-Adjuvant Conjugate (SaPAC) Platform for Precision Cancer Immunotherapy.

Wu YF; Hu JC; Hu YF; Li WJ; Rong L; Li RH; Yao Y; Hu L; Wang XL; Zhang BZ; Lu Y; Chow SF; Su C; Yau T; Chung CY; Huang JD

Jan 1, 2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)

2026PubMedDirectly related

Biomimetic nano-in-gel vaccine platform with spatiotemporal co-delivery capacity for DC maturation against immunosuppressive tumors.

Wu J; Bu X; Liu Z; Zhou Y; Zhang L; Wang Z; Cheng W; Yu Y; Xu H; Gu Q

Jan 1, 2026International journal of pharmaceutics: X

2026PubMedDirectly related

Advances in the Management of Refractory Helicobacter pylori Infection: From Antimicrobial Resistance to Precision Eradication.

Sun B; Zhou J; Feng Y; Ding X; Jiao Z; Yang W; Xu H; Guo M; Wu X; Liao H; Li M

Jan 1, 2026Gastro hep advances

2026PubMedDirectly related

Advances in immunotherapy for HPV-associated malignancies: emerging strategies and clinical progress.

Alsalloum A; Zakhareva A; Lopatnikova J; Sennikov S

Jan 1, 2026Frontiers in immunology

2026PubMedDirectly related

Light on dark matter: Epigenetic drugs as a tool to reveal the hidden antigen repertoire.

Romashin DD; Shlepova OV; Bogoslovskaya EV; Shipulin GA

Jan 1, 2026Biochemical and biophysical research communications

2026PubMedDirectly related

Harnessing novel agents to target KRAS-driven pathways in pancreatic cancer.

Kreidi J; Hoyek C; Eslinger C; Bekaii-Saab T

Jan 1, 2026Expert opinion on biological therapy

2026PubMedDirectly related

OX40 ligand-engineered dendritic cell nanovesicles potentiate antitumor immunity through dual-mode T cell activation.

Yang Z; Ding Y; Yang Y; Deng C; Yin X; Yu T; Ma J; Long Q; Ma Y

Jan 1, 2026Journal of controlled release : official journal of the Controlled Release Society